Marshall Wace’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Marshall Wace’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,958	Closed	-$206K	–	2720
2023 Q3	$206K	Sell	30,958 -70,009	-69%	-$582K	﹤0.01%	1968
2023 Q2	$915K	Sell	100,967 -174,296	-63%	-$1.54M	﹤0.01%	1750
2023 Q1	$2M	Buy	+275,263	New	+$2.04M	﹤0.01%	1459
2022 Q4	–	Sell	-115,102	Closed	-$890K	–	3592
2022 Q3	$890K	Buy	+115,102	New	+$977K	﹤0.01%	2461
2022 Q2	–	Sell	-38,110	Closed	-$304K	–	3985
2022 Q1	$304K	Buy	38,110 +33,240	+683%	+$211K	﹤0.01%	2961
2021 Q4	$27K	Buy	+4,870	New	+$36.5K	﹤0.01%	3670

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Marshall Wace's PNT Position: Q4 2023 in Review

Marshall Wace sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 30,958 shares — an estimated $206K sold.

Marshall Wace first reported a position in PNT in Q4 2021 and held it in 6 quarters. The position peaked at $2M in Q1 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Marshall Wace reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Marshall Wace sold 30,958 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $206K.
Marshall Wace first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Marshall Wace's POINT Biopharma Global Inc. Common Stock position peaked at $2M in Q1 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Marshall Wace's 13F filing for Q4 2023, filed 14 Feb 2024.